Cyclacel Pharmaceuticals Equity 2024

Cyclacel Pharmaceuticals Aktienanalyse

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals Inc was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company was established by Dr. David Glover, an experienced biotechnology expert, and Dr. Paul Andrews, an oncology pioneer. Cyclacel Pharmaceuticals is a company specializing in the research and development of cancer drugs. It has two main divisions: clinical drug development and drug discovery. The company's business model is to develop innovative cancer drugs to meet the needs of patients with various types of cancer. The company utilizes an innovative approach by researching and developing cyclin-dependent kinase inhibitors (CDKIs) that aim to exploit the specific vulnerabilities of cancer cells. Cyclacel Pharmaceuticals currently offers four products: Seliciclib, Sapacitabin, CYC065, and CYC140. Seliciclib is a CDKI inhibitor that is currently in clinical development and being studied in a phase 2 trial for advanced cancer patients. Sapacitabin is a CDKI stabilizer that is currently being studied in a phase 3 trial for patients with acute myeloid leukemia (AML). CYC065 is a CDKI inhibitor that is still in preclinical development and currently being tested in drug discovery. CYC140 is another CDKI target that is in preclinical development and aims to eliminate cancer cells. Cyclacel Pharmaceuticals has achieved many significant milestones in its history, including the FDA approval of Seliciclib and Sapacitabin as orphan drugs for the treatment of AML. The company has also formed important partnerships with other pharmaceutical companies to further develop and distribute its drug class. Overall, Cyclacel Pharmaceuticals pursues a promising strategy in the fight against cancer through the research and development of CDKI regulators. Although the company has only a few products on the market, it is well positioned to continue growing and developing innovative drugs that can improve patients' lives. Cyclacel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cyclacel Pharmaceuticals's Equity

Cyclacel Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cyclacel Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cyclacel Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cyclacel Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cyclacel Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cyclacel Pharmaceuticals stock

What is the equity of Cyclacel Pharmaceuticals this year?

Cyclacel Pharmaceuticals has equity of 606,999.99 USD this year.

What was the equity of Cyclacel Pharmaceuticals compared to the previous year?

The equity of Cyclacel Pharmaceuticals has increased/decreased by -96.97% decreased compared to the previous year.

What impact does a high equity have on investors of Cyclacel Pharmaceuticals?

A high equity is advantageous for investors of Cyclacel Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cyclacel Pharmaceuticals?

A low equity can be a risk for investors of Cyclacel Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cyclacel Pharmaceuticals affect the company?

An increase in equity of Cyclacel Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cyclacel Pharmaceuticals affect the company?

A reduction in equity of Cyclacel Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cyclacel Pharmaceuticals?

Some factors that can affect the equity of Cyclacel Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cyclacel Pharmaceuticals so important for investors?

The equity of Cyclacel Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cyclacel Pharmaceuticals take to change the equity?

To change equity, Cyclacel Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cyclacel Pharmaceuticals pay?

Over the past 12 months, Cyclacel Pharmaceuticals paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 14.56 %. For the coming 12 months, Cyclacel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyclacel Pharmaceuticals?

The current dividend yield of Cyclacel Pharmaceuticals is 14.56 %.

When does Cyclacel Pharmaceuticals pay dividends?

Cyclacel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cyclacel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyclacel Pharmaceuticals located?

Cyclacel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyclacel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyclacel Pharmaceuticals from 8/1/2016 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2016.

When did Cyclacel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2016.

What was the dividend of Cyclacel Pharmaceuticals in the year 2023?

In the year 2023, Cyclacel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cyclacel Pharmaceuticals pay out the dividend?

The dividends of Cyclacel Pharmaceuticals are distributed in USD.